ES2044976T3 - Preparados activos frente a infecciones por pseudomonas aeruginosa y procedimiento para su fabricacion. - Google Patents

Preparados activos frente a infecciones por pseudomonas aeruginosa y procedimiento para su fabricacion.

Info

Publication number
ES2044976T3
ES2044976T3 ES87890135T ES87890135T ES2044976T3 ES 2044976 T3 ES2044976 T3 ES 2044976T3 ES 87890135 T ES87890135 T ES 87890135T ES 87890135 T ES87890135 T ES 87890135T ES 2044976 T3 ES2044976 T3 ES 2044976T3
Authority
ES
Spain
Prior art keywords
procedure
flagelar
vaccines
preparations
aeruginous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87890135T
Other languages
English (en)
Inventor
Friedrich Prof Dr Dorner
Johann Dr Eibl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oesterreichisches Institut fuer Haemoderivate
Original Assignee
Immuno AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno AG filed Critical Immuno AG
Application granted granted Critical
Publication of ES2044976T3 publication Critical patent/ES2044976T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Abstract

SE DESCRIBEN PREPARACIONES ACTIVAS CONTRA LAS INFECCIONES PRODUCIDAS POR LA PSEUDOMONA AERUGINOSA, ES DECIR VACUNAS PARA LA INMUNIZACION ACTIVA Y PREPARACIONES DESTINADAS A LA PROTECCION PASIVA QUE CONTIENEN ANTICUERPOS, Y PROCEDIMIENTO PARA SU PREPARACION. LAS VACUNAS CONTIENEN ANTIGENO H FLAGELAR PROTECTOR DEL SEROTIPO-H A Y B, QUE CONSISTEN EN COMPONENTES MONOMEROS, ESTANDO CONSTITUIDO CADA UNO DE LOS COMPONENTES MONOMEROS POR AMINOACIDOS DETERMINADOS CON UNA SECUENCIA DE AMINOACIDOS N-TERMINAL Y PRESENTANDO UN PESO MOLECULAR DETERMINADO. LAS VACUNAS SE PREPARAN A PARTIR DE SOLUCIONES PURAS DE ANTIGENO H FLAGELAR. LAS PREPARACIONES QUE CONTIENEN INMUNOGLOBULINA G CONTIENEN ANTICUERPOS H FLAGELARES OBTENIDOS DEL PLASMA SANGUINEO DE DONANTES HUMANOS INMUNIZADOS O DE ANIMALES MAMIFEROS INMUNIZADOS. AQUELLAS PUEDEN PURIFICARSE POR UN PROCEDIMIENTO DE CROMATOGRAFIA DE AFINIDAD.
ES87890135T 1986-06-24 1987-06-15 Preparados activos frente a infecciones por pseudomonas aeruginosa y procedimiento para su fabricacion. Expired - Lifetime ES2044976T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT1716/86A AT391080B (de) 1986-06-24 1986-06-24 Verfahren zur herstellung von gegen pseudomonas aeruginosa infektionen wirksamen praeparationen

Publications (1)

Publication Number Publication Date
ES2044976T3 true ES2044976T3 (es) 1994-01-16

Family

ID=3519452

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87890135T Expired - Lifetime ES2044976T3 (es) 1986-06-24 1987-06-15 Preparados activos frente a infecciones por pseudomonas aeruginosa y procedimiento para su fabricacion.

Country Status (9)

Country Link
US (1) US4946677A (es)
EP (1) EP0252064B1 (es)
JP (2) JPH0830011B2 (es)
AT (2) AT391080B (es)
CA (1) CA1306690C (es)
DE (1) DE3782771D1 (es)
DK (1) DK173123B1 (es)
ES (1) ES2044976T3 (es)
FI (1) FI86508C (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5237053A (en) * 1986-06-24 1993-08-17 Immuno Aktiengesellschaft Preparation active against Pseudomonas aeruginosa infections and methods of producing them
AT390192B (de) * 1988-08-29 1990-03-26 Immuno Ag Gegen pseudomonas aeruginosa-infektionen wirksame praeparationen sowie immunglobuling-h|ltige, gegen bakterium pseudomonas aeruginosa wirksame praeparationen
AU5405794A (en) * 1992-10-16 1994-05-09 Brigham And Women's Hospital O-derivatized alginic acid antigens
GB9701489D0 (en) * 1997-01-24 1997-03-12 Auspharm Int Ltd Antigen
US6749831B1 (en) * 1997-05-16 2004-06-15 Medical Defense Technology, Llc Vaccine against lipopolysaccharide core
US7405039B2 (en) 2002-02-07 2008-07-29 Austin Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
EP1499712A4 (en) 2002-04-12 2008-04-16 Melbourne Health HEPATITIS B VIRUS VARIANTS WITH REDUCED SENSITIVITY TO NUCLEOSIDANALOGES AND USE THEREOF
WO2005091716A2 (en) * 2004-03-26 2005-10-06 Quark Biotech, Inc. Annexin ii and uses thereof
JP2008534020A (ja) 2005-04-08 2008-08-28 メルボルン ヘルス 抗ウイルス性のヌクレオシド剤に耐性を示すｂ型肝炎ウイルスのバリアントおよびその応用法
AU2006230802A1 (en) 2005-04-08 2006-10-12 Austin Health Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
US8173130B2 (en) * 2007-09-05 2012-05-08 Inotek Pharmaceuticals Corporation Antibodies against flagellin and uses thereof
US20100239583A1 (en) * 2009-03-04 2010-09-23 Inotek Pharmaceuticals Corporation Antibodies against flagellin and uses thereof
EP2488228A4 (en) * 2009-10-18 2018-03-21 Glycorex AB Method and product for blood treatment and purification

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674863A (en) * 1969-12-08 1972-07-04 Parke Davis & Co Polyvalent immunizing agents and methods for their production
US3987164A (en) * 1970-10-20 1976-10-19 Yuzuru Homma Method for prevention of pseudomonas aeruginosa infections
US3928565A (en) * 1971-10-19 1975-12-23 Yuzuru Homma Pharmaceutical preparation of pseudomonas aeruginosa bacterial component possessing anti-tumor and anti-infection properties
US4075321A (en) * 1973-05-04 1978-02-21 Agence Nationale De Valorisation De La Recherche (Anvar) Vaccines, the process for preparing the same and the applications thereof
FR2227861B1 (es) * 1973-05-04 1976-07-02 Anvar
JPS51133489A (en) * 1975-05-14 1976-11-19 Tokyo Daigaku Process for producing microbial components of pseudomonas aeruginosa h aving antimicrobial and antitumor activities
US4298597A (en) * 1979-09-04 1981-11-03 University Of Saskatchewan Vaccine for diarrhea caused by E. coli
JPS60248625A (ja) * 1984-05-25 1985-12-09 Mitsui Toatsu Chem Inc 抗緑膿菌モノクロ−ナル抗体、その製法ならびに用途
AT384032B (de) * 1985-01-14 1987-09-25 Immuno Ag Verfahren zur herstellung von polydispersen nativen pseudomonas-flagella(h)-antigenen (fag)
US4693891A (en) * 1985-09-09 1987-09-15 Miles Laboratories, Inc. Vaccine for Pseudomonas aeruginosa
FR2597344B1 (fr) * 1986-04-16 1989-06-23 Merieux Inst Perfectionnement au procede de purification d'antigenes proteiques de bacteries appartenant au genre bordetella, en vue de l'obtention d'un vaccin acellulaire.

Also Published As

Publication number Publication date
DE3782771D1 (de) 1993-01-07
US4946677A (en) 1990-08-07
CA1306690C (en) 1992-08-25
FI872750A0 (fi) 1987-06-22
JP2534470B2 (ja) 1996-09-18
EP0252064A3 (en) 1989-03-15
JPS635029A (ja) 1988-01-11
FI86508C (fi) 1992-09-10
DK322287D0 (da) 1987-06-24
DK322287A (da) 1987-12-25
JPH0830011B2 (ja) 1996-03-27
JPH0853367A (ja) 1996-02-27
FI86508B (fi) 1992-05-29
EP0252064B1 (de) 1992-11-25
EP0252064A2 (de) 1988-01-07
ATE82687T1 (de) 1992-12-15
AT391080B (de) 1990-08-10
ATA171686A (de) 1990-02-15
DK173123B1 (da) 2000-01-31
FI872750A (fi) 1987-12-25

Similar Documents

Publication Publication Date Title
ES2044976T3 (es) Preparados activos frente a infecciones por pseudomonas aeruginosa y procedimiento para su fabricacion.
ATE127345T1 (de) Stressproteine und verwendungen dafür.
YU48250B (sh) Postupak za pripremanje aktivne vakcine protiv lajmske bolesti
ES2091861T3 (es) Proteinas antigenicas y vacunas que las contienen para la prevencion de la coccidiosis.
DK0461177T3 (da) Humant intra-acrosomalt spermantigen til anvendelse i en svangerskabsforebyggende vaccine
ES2104535T1 (es) Vacuna que contiene proteina de membrana externa de bordetella pertussis, y metodo para elaborar tal vacuna.
MX9301675A (es) Composiciones que contienen peptidos para inducir tolerancia de las celulas t a un antigeno.
DK0412766T3 (da) Peptidfragmenter af HIV
Di Conza Protective action of passively transferred immune serum and immunoglobulin fractions against tissue invasive stages of the dwarf tapeworm, Hymenolepis nana
MX9301858A (es) Anticuerpos monoclonales neutralizantes de hiv-humano recombinante para prevencion y tratamiento de infeccion hiv.
ES2164699T3 (es) Anticuerpo lo-cd2a y usos del mismo para inhibir la activacion y la proliferacion de las celulas t.
DK0653939T3 (da) Anvendelse af en Hymenoptera-gift til fremstilling af et medikament til behandling af DNA-virusinfektioner
DK56389A (da) Forhindring og behandling af retroviralt frembragte sygdomme
Warnock et al. Immunoglobulin classes of antibodies to Aspergillus fumigatus in patients with pulmonary aspergillosis
KR890016165A (ko) 수도모나스 아에루기노사(Pseudomonas aeruginosa)에 대한 모노클로날 항체, 이의 제조방법 및 용도
KR900011477A (ko) 항-트립타아제 항체 및 이것을 사용한 후천성 면역결핍증 치료용 조성물
FR2694938B1 (fr) Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
Eliakim et al. The Complement-fixation test in bilharziasis I. The value of different extracts of Schistosoma mansoni and Fasciola hepatica worms as antigens
EP0374053B1 (fr) Médicament pour le traitement ou la prévention par immunisation passive de l'infection par le virus HIV et procédés de préparation
ES2165042T3 (es) Vacuna que contiene el virus de la artritis-encefalitis de cabra y utilizacion para inmunoproteccion contra la infeccion por hiv-1.
AR027738A1 (es) Composicion coadyuvante, composiciones de vacunas que incluyen dicha composicion coadyuvante; procedimiento de induccion de inmunorespuestas antigenicas enmamiferos y procedimiento de tratamiento donde se aplican dichas vacunas
Magee et al. Individual variability in antibody response of human volunteers to infection of the upper respiratory tract by coxsackie A-21 virus
DK0820308T3 (da) Konjugat til behandling af inflammatoriske sygdomme
Fernando et al. Immunoglobulin class of antibodies in monkeys infected with Toxocara canis
ATE175357T1 (de) Empfängnisverhütender impfstoff

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 252064

Country of ref document: ES